Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus

Background: Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having optimal cardioprotective properties. A comparative study of the various sodium-glucose co-tr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. V. Simanenkova, S. M. Minasian, T. L. Karonova, T. D. Vlasov, N. V. Timkina, А. K. Khalzova, O. S. Fuks, A. A. Shimshilashvili, V. A. Timofeeva, Yu. Yu. Borshchev, M. M. Galagudza
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2021
Materias:
Acceso en línea:https://doaj.org/article/171c503ba24247ba8cb943eae9b840f8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!